Protein therapeutics: a summary and pharmacological classification

@article{Leader2008ProteinTA,
  title={Protein therapeutics: a summary and pharmacological classification},
  author={Benjamin Leader and Quentin J. Baca and David E. Golan},
  journal={Nature Reviews Drug Discovery},
  year={2008},
  volume={7},
  pages={21-39}
}
Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in number and frequency of use since the introduction of the first recombinant protein therapeutic — human insulin — 25 years ago. Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy. This article overviews some of the key characteristics of protein therapeutics, summarizes the more than 130 protein therapeutics used… 

Drug development: longer-lived proteins.

This tutorial review introduces the concepts of physiological protein clearance from the body, and describes several chemical modification and protein engineering approaches used to improve the life span of administered protein therapeutics.

Structural aspects of therapeutic enzymes to treat metabolic disorders

An overview of the correlation between structural perturbations of these enzymes with the clinical presentation of the respective metabolic conditions, as well as a discussion of the relevant structural modification strategies engaged in improving these enzymes for replacement therapies.

Distribution and elimination of protein therapeutics: A review

The general aspects of protein therapeutics with their advantages over small-molecule drugs, functional classification of therapeutic proteins and their uses are discussed, and the pharmacokinetics of protein therapeutic proteins will be discussed in brief.

Design of next-generation protein therapeutics.

Development of therapeutic proteins: advances and challenges

All possible factors that are linked with the basis of therapeutic proteins and possible challenges that are currently being faced by scientists during the development of these therapeutic proteins are discussed.

Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

This study has comprehensively reviewed various components of chimera, such as half-life extension partners and linkers, their shortcomings, and prospective work to be undertaken for developing effective chimeric protein therapeutics.

A protein therapeutic modality founded on molecular regulation

A synthetic biology strategy for designing protein therapeutics that autonomously activate a therapeutic function in response to a specific cancer marker of choice is described and demonstrated by creating a prodrug-activating enzyme that selectively kills human cancer cells that accumulate the marker hypoxia-inducible factor 1α.
...

References

SHOWING 1-10 OF 343 REFERENCES

Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.

It is demonstrated that parameters describing the physicochemical properties of polypeptides can be used as predictors of protein aggregation and this approach could be used successfully to enhance the solubility and efficacy of a wide range of other peptide and protein therapeutics.

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

With an increasing number of therapeutic proteins moving into preclinical and clinical development, pharmacokinetic factors play an important role in the development of these macromolecules. It is

Development trends for monoclonal antibody cancer therapeutics

Trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980 are overviewed with the aim of informing future research and development for this class of therapeutics.

Improving protein therapeutics with sustained-release formulations

Using injectable depot formulaions in which the protein is encapsulated in, and released slowly from, microspheres made of biodegradable polymers can justify commercial development of proteins that, for a variety of reasons, could not be marketed as solution formulations.

Protein drug stability: a formulation challenge

The increasing use of recombinantly expressed therapeutic proteins in the pharmaceutical industry has highlighted issues such as their stability during long-term storage and means of efficacious

Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development

This review provides an overview of the molecular, biochemical, and pharmacokinetic properties and clinical development history of Mabs and details how these factors currently affect the scope and design of early clinical development strategies for these drug candidates.

Transgenic chickens as bioreactors for protein-based drugs.

Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis

Treatment with drotrecogin alfa (activated) leads to substantial reduction in mortality and has an acceptable risk/benefit ratio in septic patients at high risk of death and a large trial involving a high dose is required to determine its effect on mortality and morbidity.

A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States

The process of clinical development and regulatory review of new therapeutics in the United States was significantly changed by a number of legislative acts passed in the 1980s and 1990s. These acts

Pegaspargase: An Alternative?

  • L. Holle
  • Biology, Medicine
    The Annals of pharmacotherapy
  • 1997
Pegaspargase is a safe, effective alternative to L- asparaginase in patients who have had clinical hypersensitivity reactions to both Escherichia coli- and Erwinia carotovora-demed L-asparaginases, but should not be routinely substituted for L-Asparagin enzyme.
...